Hence, plasma LEAP2 was measured in a secondary analysis of our previously published phase 2 clinical trial comparing effects of SMM including caloric restriction and increased physical activity, without or with DJBL insertion over 12 months, with a further 12-month follow-up after DJBL removal, in adults with obesity and T2DM [55-59]. Here, LEAP2 is linked to obesity due to melanocortin 4 receptor deficiency.